144 related articles for article (PubMed ID: 20588059)
1. Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study.
Cejka D; Kodras K; Bader T; Haas M
Kidney Blood Press Res; 2010; 33(3):221-6. PubMed ID: 20588059
[TBL] [Abstract][Full Text] [Related]
2. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.
Mitsopoulos E; Ginikopoulou E; Economidou D; Zanos S; Pateinakis P; Minasidis E; Memmos D; Thodis E; Vargemezis V; Tsakiris D
Am J Nephrol; 2012; 36(3):238-44. PubMed ID: 22948280
[TBL] [Abstract][Full Text] [Related]
3. Effect of parathyroid hormone combined with gait training on bone density and bone architecture in people with chronic spinal cord injury.
Gordon KE; Wald MJ; Schnitzer TJ
PM R; 2013 Aug; 5(8):663-71. PubMed ID: 23558091
[TBL] [Abstract][Full Text] [Related]
4. Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study.
Zhang C; Wang S; Zhao S; Zhang X
Medicine (Baltimore); 2017 Nov; 96(45):e8664. PubMed ID: 29137107
[TBL] [Abstract][Full Text] [Related]
5. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.
Palcu P; Dion N; Ste-Marie LG; Goltzman D; Radziunas I; Miller PD; Jamal SA
Am J Kidney Dis; 2015 Jun; 65(6):933-6. PubMed ID: 25843705
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
9. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
10. The anabolic effect of teriparatide is undermined by low levels of high-density lipoprotein cholesterol.
Jeon YK; Kim KM; Kim KJ; Kim IJ; Lim SK; Rhee Y
Calcif Tissue Int; 2014 Feb; 94(2):159-68. PubMed ID: 23907724
[TBL] [Abstract][Full Text] [Related]
11. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
12. Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study.
Yamamoto J; Nakazawa D; Nishio S; Ishikawa Y; Makita M; Kusunoki Y; Nagai S; Fujieda Y; Takahata M; Yamada K; Yamamura T; Yotsukura A; Saito M; Shimazaki M; Atsumi T
Ther Apher Dial; 2020 Apr; 24(2):146-153. PubMed ID: 31210004
[TBL] [Abstract][Full Text] [Related]
13. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
14. [Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
Yamamoto S; Ei I; Narita I
Clin Calcium; 2016 Sep; 26(9):1301-7. PubMed ID: 27561345
[TBL] [Abstract][Full Text] [Related]
15. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
[TBL] [Abstract][Full Text] [Related]
16. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
18. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
19. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
Obermayer-Pietsch BM; Marin F; McCloskey EV; Hadji P; Farrerons J; Boonen S; Audran M; Barker C; Anastasilakis AD; Fraser WD; Nickelsen T;
J Bone Miner Res; 2008 Oct; 23(10):1591-600. PubMed ID: 18505369
[TBL] [Abstract][Full Text] [Related]
20. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
